X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Under the partnership, Avanzanite gains commercialization and distribution rights into three additional European countries, for Sibnayal (potassium citrate and potassium bicarbonate), the first approved medicinal product in Europe for distal Renal Tubular Acidosis.
Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area: Nephrology Product Name: Sibnayal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advicenne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 18, 2023
Details:
Sibnayal (potassium citrate) is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough.
Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area: Nephrology Product Name: Sibnayal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advicenne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 28, 2023
Details:
Under the terms of the agreement, FrostPharma will receive exclusive marketing rights to Sibnayal™ for the treatment of dRTA. Advicenne will receive a transfer price for the sale of its product and royalties for an amount significantly higher than 50% of future sales.
Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area: Nephrology Product Name: Sibnayal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: FrostPharma AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2022
Details:
Sibnayal™ is a multi-particulate formulation in 2mm granules, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients.
Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area: Nephrology Product Name: Sibnayal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2021
Details:
Advicenne’s lead product, ADV7103, is developed as a multi-particulate formulation in 2mm microtablets, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients to ease its administration.
Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area: Nephrology Product Name: Sibnayal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
ADV7103/Sibnayal (potassium citrate) becomes the first and only label-approved drug for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.
Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area: Nephrology Product Name: Sibnayal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
